Upadacitinib is effective in inducing clinical response and remission and is generally well tolerated in patients with ...

For patients with Crohn's disease or ulcerative colitis who have exhausted other treatment options, a new combination therapy ...

A new therapy that combines two existing drugs shows promise for patients with inflammatory bowel disease who have exhausted ...

One-year results: About 25% of patients achieved remission and 31% showed clinical response at 52 weeks on upadacitinib. Study design: Retrospective analysis of 59 patients across 13 French centers, ...

For too long you have suffered from inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Crohn’s disease.

A new combination drug therapy could help people with inflammatory bowel disease (IBD) for whom other medicines have stopped ...

When we talk about gut health, the conversation usually centers around the microbiome itself, which foods feed beneficial ...

Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.

A five-day-a-month diet successfully reduced intestinal inflammation and improved symptoms in patients with Crohn's disease.

Loss of bone mineral density can occur for a number of reasons, including genetics, aging, hormone changes, lifestyle habits, and poor nutrition. Another major factor is certain co-occurring chronic ...

While kidney complications are not always front of mind for people living with inflammatory bowel disease (IBD), they are more common than in the general population. From kidney stones to ...

Find out why certain people with inflammatory bowel disease, including Crohn’s, may want to avoid intermittent fasting and ...